Related Experiment Video
Updated: May 9, 2026
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines
Jacques Friborg1, Baiqing Lin, Chaoqun Chen
1Discovery Virology, Bristol-Myers Squibb Research and Development, Wallingford, CT 06492, USA. jacques.friborg@bms.com
Abstract:
Pegylated interferon lambda-1a (Lambda) is currently in clinical development for the treatment of chronic hepatitis C virus (HCV) infection. To gain insight into the potential mechanisms of non-responsiveness that may occur in patients treated with Lambda, HCV subgenomic replicon cell-lines with impaired susceptibility to the unpegylated recombinant (r) form of interferon (IFN) lambda-1 (rIFNλ) were isolated and characterized. The selected replicon cell populations showed a defect in the activation of the IFN-dependent JAK-STAT signaling pathway. Reduced phosphorylation of STAT proteins and lower expression levels of the cellular janus kinases Jak1 and Tyk2 were observed in these cell populations, which may account for the impaired JAK-STAT signaling and reduced antiviral responses to rIFNλ. Overall, this in vitro study provides molecular insights into the possible mechanism of viral evasion to rIFNλ in the HCV replicon cell system.
Insights
Investigating non-response to pegylated interferon lambda-1a (Lambda) for hepatitis C virus (HCV), this study identified defects in the JAK-STAT pathway in resistant HCV cells. This explains reduced antiviral responses to interferon lambda-1.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Pegylated interferon lambda-1a (Lambda) is under development for chronic hepatitis C virus (HCV) infection.
- Understanding non-responsiveness mechanisms is crucial for optimizing Lambda therapy.
Purpose of the Study:
- To investigate molecular mechanisms of non-responsiveness to interferon lambda-1 (IFNλ) in HCV.
- To characterize HCV subgenomic replicon cell-lines with impaired susceptibility to recombinant IFNλ (rIFNλ).
Main Methods:
- Isolation and characterization of HCV subgenomic replicon cell-lines resistant to rIFNλ.
- Analysis of the interferon-dependent JAK-STAT signaling pathway activation.
- Assessment of STAT protein phosphorylation and expression of Jak1 and Tyk2 kinases.
Main Results:
- Selected replicon cell populations exhibited impaired JAK-STAT signaling pathway activation.
- Reduced phosphorylation of STAT proteins was observed in resistant cells.
- Lower expression levels of cellular janus kinases Jak1 and Tyk2 were detected.
Conclusions:
- Defects in JAK-STAT signaling, specifically reduced STAT phosphorylation and lower Jak1/Tyk2 expression, contribute to HCV resistance to rIFNλ.
- These findings provide in vitro insights into viral evasion mechanisms against rIFNλ.
- This research aids in understanding non-responsiveness to interferon lambda-based therapies for HCV.
